Brokerages expect that Vital Therapies, Inc. (NASDAQ:VTL) will announce earnings of ($0.30) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Vital Therapies’ earnings, with the lowest EPS estimate coming in at ($0.31) and the highest estimate coming in at ($0.29). Vital Therapies also posted earnings of ($0.30) per share in the same quarter last year. The business is scheduled to report its next quarterly earnings results on Tuesday, August 1st.

According to Zacks, analysts expect that Vital Therapies will report full-year earnings of ($1.76) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.25). For the next fiscal year, analysts forecast that the business will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.42) to ($1.19). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Vital Therapies.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings data on Tuesday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. During the same period in the previous year, the business posted ($0.31) earnings per share.

Several analysts recently commented on the stock. Zacks Investment Research raised shares of Vital Therapies from a “sell” rating to a “hold” rating in a research note on Friday, April 14th. ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Raymond James Financial, Inc. assumed coverage on shares of Vital Therapies in a research note on Thursday, May 18th. They set an “outperform” rating and a $6.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $8.00.

In other news, Director Muneer A. Satter purchased 10,000 shares of Vital Therapies stock in a transaction that occurred on Tuesday, June 6th. The stock was acquired at an average price of $3.19 per share, for a total transaction of $31,900.00. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Muneer A. Satter purchased 20,000 shares of Vital Therapies stock in a transaction that occurred on Wednesday, June 7th. The stock was purchased at an average price of $3.20 per share, with a total value of $64,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 108,400 shares of company stock valued at $338,153. 29.88% of the stock is owned by insiders.

Several large investors have recently modified their holdings of VTL. UBS Oconnor LLC purchased a new stake in shares of Vital Therapies during the first quarter valued at approximately $800,000. SG Americas Securities LLC purchased a new stake in shares of Vital Therapies during the first quarter valued at approximately $167,000. Bank of New York Mellon Corp increased its stake in shares of Vital Therapies by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock valued at $352,000 after buying an additional 9,120 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Vital Therapies by 1.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after buying an additional 1,157 shares during the period. Finally, FMR LLC increased its stake in shares of Vital Therapies by 102.9% in the first quarter. FMR LLC now owns 2,957,878 shares of the company’s stock valued at $11,832,000 after buying an additional 1,500,000 shares during the period. Institutional investors and hedge funds own 26.62% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/12/vital-therapies-inc-vtl-expected-to-post-earnings-of-0-30-per-share.html.

Shares of Vital Therapies (VTL) traded down 5.36% on Wednesday, hitting $2.65. The company had a trading volume of 204,229 shares. The stock’s market cap is $111.85 million. The company has a 50-day moving average of $3.01 and a 200 day moving average of $4.02. Vital Therapies has a 12 month low of $2.25 and a 12 month high of $7.36.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.